Get your daily dose of health and medicine every weekday with STAT’s free newsletter, Morning Rounds. Sign up here.
Good morning and happy Monday. The landscape of American public health is shifting beneath our feet this week. From the corridors of the FDA to the highest court in the land, and from the spread of viral misinformation to the emergence of rare zoonotic skin conditions, there is much to unpack. Grab your coffee; it’s going to be a busy week.
I. Main Facts: A Time of Institutional Turbulence
The federal health apparatus is currently navigating a period of unprecedented volatility. At the center of the storm is the Food and Drug Administration (FDA), which appears to be facing a significant leadership transition. Multiple reports surfaced late Friday indicating that President Trump has finalized a plan to dismiss FDA Commissioner Marty Makary.
Makary, who has served in the role for just over a year, has presided over a tenure characterized by ambitious policy goals—and, inevitably, significant friction. His departure would mark yet another high-profile exit within the health department overseen by Robert F. Kennedy Jr.
Beyond the agency’s internal drama, the FDA is simultaneously defending its core regulatory authority before the Supreme Court. The judiciary’s impending decision on the abortion medication mifepristone threatens to rewrite the rules of drug approval, potentially undermining the FDA’s long-standing mandate to determine the safety and efficacy of pharmaceuticals based on scientific evidence rather than political pressure.
II. Chronology of a Leadership Exit
The writing on the wall for Commissioner Makary began to appear as early as the end of last week. While political maneuvers of this magnitude are often shrouded in secrecy, the "leaks" in Washington rarely lack substance.
- Mid-Week: Whispers of dissatisfaction within the administration regarding the FDA’s regulatory pace began to circulate in D.C. circles.
- Friday Morning: A scheduled public appearance was the litmus test for Makary’s status. The Commissioner was slated to deliver an address at an annual 5K race, followed by a run with agency staff.
- Friday Afternoon: The no-show. Sources close to the agency confirmed to STAT’s Lizzy Lawrence that Makary was absent, fueling speculation that his resignation or termination was imminent.
- Friday Evening: Multiple reports confirmed that President Trump had signed off on the dismissal, signaling the end of a turbulent year at the agency’s helm.
The swiftness of this exit suggests that the administration is eager to pivot, though the long-term impact on FDA staff morale remains a primary concern for public health observers.
III. Supporting Data: The Mifepristone Legal Battle
The tension surrounding the FDA is not merely about personnel; it is about the fundamental power of the agency to regulate medicine. The Supreme Court is expected to take action today regarding the mail-order distribution of mifepristone, following a week-long stay on a lower court’s injunction.
The legal stakes are immense. In 2023, the FDA updated its regulatory framework to allow mifepristone to be dispensed without an in-person visit, citing extensive scientific data regarding the drug’s safety profile. This decision has become a flashpoint for legal experts and stakeholders.
The Amicus Brief Consensus
Last week, a coalition of unlikely allies—including the pharmaceutical lobby, former FDA commissioners, and more than two dozen legal scholars—filed amicus briefs in support of the agency. The data presented in these briefs underscores a consistent theme:
- Regulatory Precedent: The FDA has maintained the authority to approve and regulate drugs for decades without congressional interference in individual drug labels.
- Scientific Rigor: The 2023 rule change was not a political maneuver but a evidence-based response to the changing landscape of telehealth and accessibility.
- The Slippery Slope: Experts argue that if the Court allows judicial interference in FDA-approved labeling, it could destabilize the entire pharmaceutical industry, opening the door for litigation against any medication based on ideological disagreement.
IV. The Digital Front: Misinformation and Health
As traditional institutions grapple with policy, the battle for public perception is being fought online. Epidemiologist Katrine Wallace, a prominent voice in the digital fight against medical misinformation, has highlighted a troubling trend: the "conspiracy ecosystem" is moving faster than the pathogens themselves.
Case Study: The Hantavirus "Cure"
When rumors began to spread that ivermectin—a drug repeatedly debunked as a treatment for viral infections during the Covid-19 pandemic—could be effective against the hantavirus, the misinformation cycle hit warp speed.
"At this point, the speed of it barely surprises me anymore," Wallace wrote in a First Opinion essay. "The actual facts of the outbreak almost immediately became secondary."
The data suggests that post-pandemic, the architecture of online conspiracy theories has solidified. Misinformation is no longer an accidental byproduct of social media; it is a structured, accelerated industry. By the time scientists attempt to issue a correction, the false narrative has often reached millions, making the work of public health experts increasingly like a game of "whack-a-mole."
V. Implications: Rare Diseases and Public Health Equity
The week also brings concerns regarding an emerging dermatological condition among men who have sex with men (MSM) in Europe. Dermatophilosis, a bacterial skin disease more commonly associated with livestock ("rain rot"), has been diagnosed in over 25 individuals in France and Spain.
Clinical vs. Social Implications
Demetre Daskalakis, former HIV prevention leader at the CDC, noted that the situation is reminiscent of the early days of the 2022 mpox outbreak. While the current cases of dermatophilosis are clinically milder, the diagnostic challenge is significant. Physicians are now forced to navigate the question: What does this mean for the clinical world? The lack of clear animal-to-human transmission pathways in these cases warrants immediate investigation to prevent further clusters.
Bridging the Gap: California’s Diaper Initiative
On a brighter note regarding public health equity, California Governor Gavin Newsom announced a new program to provide 400 diapers—roughly a month’s supply—to families at hospital discharge.
Launching in the next fiscal year across 65 to 75 hospitals serving low-income populations, the program aims to address a fundamental social determinant of health. Diaper need is a quiet but pervasive issue that contributes to maternal stress and infant health outcomes. California joins Tennessee and Delaware in adopting this model, suggesting a growing trend of states using targeted, tangible interventions to improve the lives of vulnerable populations.
VI. The Connection Between Menstrual Health and Psychiatry
Finally, a landmark study published in JAMA Network Open has provided the most robust data to date on the link between premenstrual disorders (PMD) and psychiatric illness.
Key Findings:
- Scope: The study analyzed 3.6 million women in Sweden over a 21-year period.
- The Link: Approximately 48% of individuals with a PMD diagnosis had a prior psychiatric diagnosis, compared to 30% in the control group.
- Bidirectional Risk: The correlation works both ways—those with pre-existing psychiatric conditions were significantly more likely to develop PMD later in life.
- Specific Disorders: The risk was most pronounced for anxiety and depression, though correlations were also noted for ADHD and bipolar disorder.
This research suggests that the biological mechanisms governing hormonal regulation and neurological health are deeply intertwined. For clinicians, this underscores the necessity of a holistic approach to reproductive health, treating the menstrual cycle not as a siloed biological event, but as a critical component of a patient’s overall mental health profile.
Conclusion: Looking Ahead
As we move through the week, the underlying theme is clear: the institutions we rely on for stability are under immense pressure. Whether it is the FDA fighting to maintain its scientific integrity in the face of political change, or the medical community working to debunk a digital misinformation ecosystem, the need for transparency, scientific rigor, and public trust has never been higher.
Stay tuned to STAT for continuing coverage on these developments. Your health—and the policies that govern it—remain our priority.
